The estimated Net Worth of Derek Jantz is at least $43 Milion dollars as of 7 June 2022. Dr Jantz owns over 41,744 units of Precision BioSciences stock worth over $42,777,242 and over the last 5 years he sold DTIL stock worth over $187,600.
Dr has made over 14 trades of the Precision BioSciences stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 41,744 units of DTIL stock worth $438,312 on 7 June 2022.
The largest trade he's ever made was exercising 43,028 units of Precision BioSciences stock on 12 May 2021 worth over $1,721. On average, Dr trades about 22,335 units every 56 days since 2019. As of 7 June 2022 he still owns at least 4,074,023 units of Precision BioSciences stock.
You can see the complete history of Dr Jantz stock trades at the bottom of the page.
Dr. Derek Jantz Ph.D. is the Co-Founder, Chief Scientific Officer & Director at Precision BioSciences.
Dr D is 45, he's been the Co-Founder a Chief Scientific Officer & Director of Precision BioSciences since . There are 4 older and 3 younger executives at Precision BioSciences. The oldest executive at Precision BioSciences, Inc. is Dr. David S. Thomson Ph.D., 59, who is the Chief Operating Officer.
Derek's mailing address filed with the SEC is C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM, NC, 27701.
Over the last 6 years, insiders at Precision BioSciences have traded over $352,500 worth of Precision BioSciences stock and bought 224,670 units worth $1,909,002 . The most active insiders traders include Raymond F Schinazi, Llc Fmr a Michael Amoroso. On average, Precision BioSciences executives and independent directors trade stock every 22 days with the average trade being worth of $357,735. The most recent stock trade was executed by Dario Scimeca on 7 June 2024, trading 301 units of DTIL stock currently worth $3,161.
Precision BioSciences, Inc., a clinical stage gene editing company, develops vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which a specific type of immune cell, called a T cell, is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Precision BioSciences executives and other stock owners filed with the SEC include: